Osteopenia. Postmenopausal osteoporosis
Conditions
Interventions
Intervention 1: Intervention group: Daily intake of 5 Oligopin capsules for 12 weeks (2 with breakfast, 2 with lunch, 1 with dinner) (Each capsule contains 50 mg of French pine bark extract). Interven
Treatment - Drugs
Placebo
Intervention group: Daily intake of 5 Oligopin capsules for 12 weeks (2 with breakfast, 2 with lunch, 1 with dinner) (Each capsule contains 50 mg of French pine bark extract)
Control group: Daily intake of 5 capsules containing water for 12 weeks (2 with breakfast, 2 with lunch, 1 with dinner) (quite similar to pine bark extract capsule)
Sponsors
Tehran University of Medical Sciences, Vice Chancellor of Research, International Campus
Eligibility
Sex/Gender
Female
Age
50 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Postmenopausal women; Age: between 50-65 years; With a diagnosis of osteopenia. Osteopenia was defined as bone mineral density T-score at the spine and/or hip between 1 to 2.5 SD below the young normal ex-matched areal BMD of the reference database (According to the WHO); Normal function of thyroid, liver, and kidney. Exclusion criteria: Report of fractures during the study; unwilling to continue participate in the project; Any visible side effects of supplements; The history of bone disease (Paget's disease, osteomalacia, etc.); History of chronic diseases, including cancer, diabetes, kidney failure, liver disease, systemic inflammatory disease, degenerative joint diseases and rheumatologic disorders;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Procollagen type I N-terminal propeptide (PINP). Timepoint: Before the intervention and immediately after the intervention. Method of measurement: ELISA.;Cross-Linked Carboxy-Terminal Telopeptide of Type I Collagen. Timepoint: Before the intervention and immediately after the intervention. Method of measurement: ELISA.;Bone alkaline phosphatase (BAP). Timepoint: Before the intervention and immediately after the intervention. Method of measurement: ELISA.;Receptor activator of nuclear factor kappa-B ligand (RANKL). Timepoint: Before the intervention and immediately after the intervention. Method of measurement: ELISA.;Osteoprotegerin (OPG). Timepoint: Before the intervention and immediately after the intervention. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Before the intervention and immediately after the intervention. Method of measurement: digital scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Bahman Panahande
Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of
Outcome results
None listed